STOCK TITAN

Lineage Cell Therapeutics Inc - LCTX STOCK NEWS

Welcome to our dedicated news page for Lineage Cell Therapeutics (Ticker: LCTX), a resource for investors and traders seeking the latest updates and insights on Lineage Cell Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Lineage Cell Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Lineage Cell Therapeutics's position in the market.

Rhea-AI Summary
Lineage Cell Therapeutics, Inc. CEO to present at Baird's 2023 Global Healthcare Conference and H.C. Wainwright 25th Annual Global Investment Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences earnings
Rhea-AI Summary
Lineage Cell Therapeutics and Cancer Research UK announce positive results from a clinical study of VAC2 in advanced non-small cell lung cancer (NSCLC). Five out of eight patients treated had a best response of stable disease, and three demonstrated progressive disease. No serious adverse events were reported. Three patients reached the 2-year survival endpoint. Further analyses are being conducted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.34%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.11%
Tags
conferences earnings
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.46%
Tags
conferences
Lineage Cell Therapeutics Inc

NYSE:LCTX

LCTX Rankings

LCTX Stock Data

245.09M
139.57M
4.13%
43.95%
5.51%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Carlsbad

About LCTX

biotime, inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies developed from what we believe to be the world's premier collection of pluripotent cell assets. the foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. pluripotent cells have potential application in many areas of medicine with large unmet patient needs, including various age-related degenerative diseases and degenerative conditions for which there presently are no cures. unlike pharmaceuticals that require a molecular target, therapeutic strategies based on the use of pluripotent cells are generally aimed at regenerating or replacing affected cells and tissues, and therefore may have broader applicability than pharmaceutical products.